Atty Dkt. No.: FOCS-001 USSN: 09/996,187

## **AMENDMENTS TO THE CLAIMS:**

1. (Currently Amended) A method for producing and evaluating a phenotype of a microbial bioactive molecule in the presence or absence of a compound comprising the steps of:

- a) providing a nucleic acid sequence comprising a bioactive molecule;
- b) expressing the bioactive molecule encoded by the nucleic acid sequence obtained in step (a),

<u>system of a nucleic acid comprising a sequence encoding the microbial bioactive molecule</u>, wherein the <u>expressed microbial</u> bioactive molecule has a detectable phenotype;

- e) contacting the <u>microbial</u> bioactive molecule <u>produced</u> obtained in step (b) with a compound; and
- detecting the phenotype <u>a functional activity</u> of the <u>microbial</u> bioactive molecule in the presence or absence of the compound-contacted in step (c);

wherein the functional activity of the microbial bioactive molecule in the presence of absence of the compound is indicative of a phenotype of the microbial bioactive molecule.

- 2. (Currently Amended) The method of claim 1, wherein the <u>microbial</u> bioactive molecule is selected from the group consisting of: a viral molecule, a bacterial molecule, a fungal molecule, <u>or</u> a protozoal molecule, <u>a human molecule</u> and <u>an animal molecule</u>.
- 3. (Withdrawn) The method of claim 1, wherein the <u>microbial</u> bioactive molecule is a protein further comprising a retrovirus protein, a herpesvirus protein, a hantavirus protein, a hepatitis virus protein, an influenza protein, a myxovirus protein, a picomavirus protein, an adenovirus protein, a poxvirus protein, a flavivirus protein or a coronavirus protein.
- 4. (Withdrawn) The method of claim 1, wherein the <u>microbial</u> bioactive molecule is a <u>protein</u> further comprising a streptococcus protein, a staphylococcus protein, an enterococus protein, a neisseria protein, a salmonella protein, a <u>mycubacteria</u> protein, a bacillus protein, a mycoplasma protein, a chlamydia protein, a francisella protein, a pasturella protein, a brucella protein, a

Atty Dkt. No.: FOCS-001

USSN: 09/996,187

pseudomonas protein, a listeria protein, a clostridium protein, a yersinia protein, a vibrio protein, a shigella protein, or an enterobacteriaceae protein.

- 5. (Withdrawn) The method of claim 1, wherein the <u>microbial</u> bioactive molecule is a protein further comprising a plasmodium protein, a trypanosome protein, or a crytosporydium protein.
- 6. (Withdrawn) The method of claim 1, wherein the <u>microbial</u> bioactive molecule is a <u>protein</u> further comprising a candida protein, a cryptococcus protein, a malassezia protein, a histoplasma protein, a coccidioides protein, a hyphomyces protein, a blastomyces protein, an asp ergillus protein, a penicillium protein, a pseudallescheria protein, a fusarium protein, a paecilomyces protein, a mucor/rhizopus protein, a pneumocystis protein, a rhinosporidium protein, a sporothrix protein, a trichophyton protein, a microsporum protein, a epidermophyton protein, a basidiobolus protein, a conidiobolus protein, a rhizopus protein, a cunninghamelia protein, a paracoccidioides protein, a pseudallescheria protein, or a rhinosporidium protein.
- 7. (Currently Amended) The method of claim 1, wherein the nucleic acid sequence encoding the biomolecule microbial bioactive molecule is deoxyribonucleic acid or ribonucleic acid.
- 8. (Currently Amended) The method of claim 1 or claim 7, wherein the nucleic acid sequence encoding the a-bioactive molecule further comprises transfer RNA an messenger RNA or polyA+RNA.
- 9. (Currently Amended) The method of claim 1, wherein the <u>microbial</u> bioactive molecule <u>is</u> further comprises a protein, <u>a protein or</u> a glycoprotein, <u>a polysaccharide</u>, a mucopolysaccharide, a lipoprotein, a carbohydrate, or a nucleic acid.
- 10. (Currently Amended) The method of claim 1, wherein the <u>cell-free in vitro transcription</u>

  and translation system is bioactive molecule encoded by the nucleic acid is expressed in a cell-free

  a eukaryotic cell lysate translation system.

Atty Dkt. No.: FOCS-001 USSN: 09/996,187

11. (Currently Amended) The method of claim 1, wherein the <u>cell-free in vitro transcription</u>

and translation system is bioactive molecule encoded by the nucleic acid is expressed in a cell-free

a prokaryotic cell lysate translation system.

- 12. (Currently Amended) The method of claim 10, wherein the <u>cell-free in vitro transcription</u> and translation system is <u>bioactive molecule encoded by the amplified nucleic acid sequence is expressed in a cell-free a reticulocyte lysate translation</u> system.
- 13. (Currently Amended) The method of claim 12, wherein the <u>cell-free in vitro transcription</u>

  and translation system is bioactive molecule encoded by the amplified nucleic acid sequence is

  expressed in a cell-free <u>a rabbit</u> reticulocyte lysate eoupled transcription/translation system.
- 14. (Currently Amended) The method of claim 13, wherein the bioactive molecule encoded by the nucleic acid sequence and expressed in a cell-free reticulocyte lysate coupled transcription/translation system is a nucleic acid selected from the group consisting of: the microbial bioactive molecule is produced from a deoxyribonucleic acid, a ribonucleic acid, a polyA+RNA, a messenger RNA tRNA, and an rRNA.
- 15. (Currently Amended) The method of claim 1, wherein the nucleic acid sequence comprising a sequence encoding that encodes the microbial bioactive molecule is operably linked to further comprises a second nucleic acid sequence operably linked to said bioactive molecule.
- 16. (Currently Amended) The method of claim 15, wherein the second nucleic acid <u>comprises</u> a sequence <u>comprises</u> encoding a regulatory element.
- 17. (Currently Amended) The method of claim 15, wherein the second nucleic acid sequence comprises a <u>sequence encoding a</u> purification motif.
- 18. (Currently Amended) The method of claim 15, wherein the second nucleic acid <u>comprises</u>

  <u>a</u> sequence <u>encodes</u> <u>encoding</u> a gene product or fragment thereof comprising a purification motif.

Atty Dkt. No.: FOCS-001 USSN: 09/996.187

19. (Currently Amended) The method of claim 1, wherein the <u>compound is</u> bioactive molecule is contacted with a compound selected from the group consisting of: an anti-viral compound, an anti-bacterial compound, an anti-fungal compound, an anti-cancer compound, an immunosuppressive compound, a hormone, a cytokine, a lymphokine, a chemokine, an enzyme, a polypeptide, a polynucleotide, and <u>or</u> a nucleoside analogue.

- 20. (Currently Amended) The method of claim 1, wherein detecting the phenotype the functional activity of the microbial bioactive molecule further-comprises assaying the an enzymatic activity of the microbial bioactive molecule.
- 21. (Currently Amended) The method of claim 20 1, wherein said detecting is performed in across a concentration range of compound to assess a sensitivity or resistance phenotype of the microbial bioactive molecule assaying the enzymatic activity of the bioactive molecule further comprises assaying the bio active molecule for a resistance phenotype to the compound.
  - 22. 25.(Canceled)
- 26. (Currently Amended) The method of claim 1, wherein prior to said producing, the method further comprises the method is preceded by the step of:

amplifying a nucleic acid sequence in a cell-free system, wherein the nucleic acid comprises a sequence encoding comprises a microbial bioactive molecule.

- 27. (Currently Amended) The method of claim 1 26, wherein said amplifying is by the nucleic acid encoding a bioactive molecule is amplified by a reaction selected from the group consisting of: a polymerase chain reaction, a ligase chain reaction, a transcription mediated amplification reaction, a nucleic acid sequence based amplification reaction, and or a strand displacement amplification reaction.
- 28. (Currently Amended) The method of claim 1, wherein <u>prior to said producing, the</u>

  <u>method further comprises</u> amplifying the <u>a</u> nucleic acid encoding the <u>microbial bioactive molecule</u>

  <u>biomolecule comprises a polymerase chain reaction further comprising using</u> one or more nested primer sets.

Atty Dkt. No.: FOCS-001

USSN: 09/996,187

29. (Withdrawn) The method of claim 1 26, wherein said amplifying the nucleic acid encoding the biomolecule uses a primer having a nucleic acid sequence of SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.

30. (Currently Amended) The method of claim 1 or claim 26, wherein the nucleic acid comprising a sequence encoding the microbial bioactive molecule is obtained by the method is preceded by the step of: extracting one or more specimen specemins from a patient afflicted with a disease state, wherein the specemins comprise a bioactive molecule associated with the disease state.

## 31. - 34. (Canceled)

35. (New) A method for evaluating a phenotype of a microbial bioactive molecule in the presence or absence of a compound comprising the steps of:

amplifying from a sample a nucleic acid comprising a sequence encoding a microbial bioactive molecule, wherein the microbial bioactive molecule has a detectable phenotype, said amplifying using one or more nested primer sets to produce an amplified nucleic acid product;

producing the microbial bioactive molecule by cell-free in vitro transcription and translation system of the amplified nucleic acid product;

contacting the microbial bioactive molecule produced with a compound; and

detecting a functional activity of the microbial bioactive molecule in the presence or absence of a compound;

wherein the functional activity of the microbial bioactive molecule in the presence of absence of the compound is indicative of a phenotype of the microbial bioactive molecule.

- 36. (New) The method of claim 35, wherein said producing proceeds without purification of the amplified nucleic acid product.
  - 37. (New) The method of claim 35, wherein the functional activity is an enzymatic activity.
  - 38. (New) The method of claim 35, wherein the microbial bioactive molecule is a viral molecule.

Atty Dkt. No.: FOCS-001 USSN: 09/996,187

39. (New) The method of claim 39, wherein the viral molecule is a protein or an mRNA.

40. (New) The method of claim 35, wherein the microbial bioactive molecule is a bacterial molecule, a fungal molecule, or a protozoal molecule.

41. (New) The method of claim 40, wherein the microbial bioactive molecule is a protein or a RNA.

42. (New) The method of claim 35, wherein the cell-free in vitro transcription and translation system is a eukaryotic cell lysate system.

43. (New) The method of claim 35, wherein the sample is from a patient infected with a microbe.